Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: First In-Human Phase I Trial of NHS-IL12 in Patients With Metastatic Solid Tumors
Brief Summary:
Background:
- The experimental drug NHS-IL12 may help the immune system become more active and kill cancer cells that have not responded to standard treatments. NHS-IL12 has been designed to cause less severe side effects than other anticancer drugs, and may be more effective. More research is needed to test NHS-IL12 in people who have solid tumors that have not responded to treatment.
Objectives:
- To test the safety and effectiveness of NHS-IL12 as a treatment for solid tumors which have not responded to standard treatments.
Eligibility:
- Individuals at least 18 years of age with solid tumors that have not responded to standard treatments.
Design: